A quantitative key-opinion-leader analysis of innovation barriers in probiotic research and development: valorisation and improving the tech transfer cycle

This study demonstrates that the probiotic research cycle is faulty due to specific barriers and bypasses, and that innovation is hampered in all domains of the valorisation cycle. Eleven main barriers were identified, with “difficulty in demonstrating clinical efficacy” being the most significant inhibiting factor. Other barriers could be classified as fundamental research barriers, clinical research barriers, financial barriers, regulatory barriers, collaboration barriers, marketing barriers and product barriers. Using this barrier approach, inhibiting factors are identified which allows subsequent action to be taken to re-establish the natural cycle of innovation. Graphical abstract
Source: PharmaNutrition - Category: Nutrition Source Type: research